BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16390748)

  • 1. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer.
    Boxer RS; Kenny AM; Dowsett R; Taxel P
    Aging Male; 2005; 8(3-4):207-12. PubMed ID: 16390748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
    BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer.
    Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
    J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1036-1044. PubMed ID: 31067013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
    Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
    Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy.
    Uth J; Hornstrup T; Schmidt JF; Christensen JF; Frandsen C; Christensen KB; Helge EW; Brasso K; Rørth M; Midtgaard J; Krustrup P
    Scand J Med Sci Sports; 2014 Aug; 24 Suppl 1():105-12. PubMed ID: 24944134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
    Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
    Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
    Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
    BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    J Urol; 2011 Oct; 186(4):1291-7. PubMed ID: 21849187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in prostate cancer patients taking androgen deprivation therapy.
    Dacal K; Sereika SM; Greenspan SL
    J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in body composition during androgen deprivation therapy for prostate cancer.
    Smith MR; Finkelstein JS; McGovern FJ; Zietman AL; Fallon MA; Schoenfeld DA; Kantoff PW
    J Clin Endocrinol Metab; 2002 Feb; 87(2):599-603. PubMed ID: 11836291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
    Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
    J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
    Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
    BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.
    Stoch SA; Parker RA; Chen L; Bubley G; Ko YJ; Vincelette A; Greenspan SL
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2787-91. PubMed ID: 11397888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Turner D; Newton RU
    Prostate Cancer Prostatic Dis; 2009; 12(2):198-203. PubMed ID: 18852703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study.
    Levy ME; Perera S; van Londen GJ; Nelson JB; Clay CA; Greenspan SL
    Urology; 2008 Apr; 71(4):735-9. PubMed ID: 18279933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer.
    Girard D; Marino FE; Cannon J
    Clin Physiol Funct Imaging; 2014 May; 34(3):209-17. PubMed ID: 24119067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.
    Padhi D; Higano CS; Shore ND; Sieber P; Rasmussen E; Smith MR
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1967-75. PubMed ID: 24971661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.